ACOG

Alpha Cognition Inc

Sep 22 • 02:29PM ET

8.41

+0.39 4.85 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-1.59	Insider Own	19.68%	Shs Outstand	16.02M	Perf Week	-11.02%
Market Cap	135.89M	Forward P/E	-	EPS next Y	-1.12	Insider Trans	0.47%	Shs Float	12.47M	Perf Month	1.80%
Enterprise Value	96.43M	PEG	-	EPS next Q	-0.46	Inst Own	39.27%	Short Float	0.65%	Perf Quarter	-6.57%
Income	-20.01M	P/S	29.61	EPS this Y	28.47%	Inst Trans	-26.24%	Short Ratio	1.21	Perf Half Y	56.59%
Sales	4.59M	P/B	4.22	EPS next Y	22.15%	ROA	-84.80%	Short Interest	0.08M	Perf YTD	42.76%
Book/sh	1.99	P/C	3.44	EPS next 5Y	-	ROE	-131.23%	52W High	12.63 -33.41%	Perf Year	-18.14%
Cash/sh	2.44	P/FCF	-	EPS past 3/5Y	39.59% -101.17%	ROIC	-62.75%	52W Low	3.75 124.23%	Perf 3Y	-56.42%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	68.82%	Volatility	11.42% 6.87%	Perf 5Y	-
Dividend TTM	-	EV/Sales	21.01	EPS Y/Y TTM	53.49%	Oper. Margin	-315.92%	ATR (14)	0.67	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.40	Sales Y/Y TTM	-	Profit Margin	-436.39%	RSI (14)	44.79	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	14.69	EPS Q/Q	-85.99%	SMA20	-3.36%	Beta	2.68	Target Price	20.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-7.50%	Rel Volume	0.80	Prev Close	8.02
Employees	-	LT Debt/Eq	0.00	Earnings	Aug 14 BMO	SMA200	15.77%	Avg Volume	67.35K	Price	8.41
IPO	Jun 28, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-41.30% 2.60%	Trades		Volume	43,006	Change	4.85%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-25	Initiated	H.C. Wainwright	Buy	$20

Aug-28-25 01:00PM	Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences (Business Wire)
Aug-15-25 05:10PM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025 (Newsfile) +5.56%
Aug-14-25 06:55PM	Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -19.92%
08:30AM	Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update (Business Wire)
Aug-04-25 08:30AM	Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview (Business Wire)
08:30AM	Loading…
Jul-29-25 08:30AM	Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL (Benzgalantamine) for Alzheimers Disease (Business Wire)
Jul-08-25 08:30AM	Alpha Cognition to Present ZUNVEYL (Benzgalantamine) Study Data at Alzheimers Association International Conference (Business Wire) -5.07%
Jul-04-25 12:00PM	What Makes Alpha Cognition Inc. (ACOG) a New Strong Buy Stock (Zacks)
Jul-01-25 05:05PM	Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury (Business Wire) +16.20%
09:40AM	Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-16-25 09:55AM	Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross? (Zacks)
Jun-06-25 04:31PM	Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory (Insider Monkey)
May-19-25 10:25AM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025 (Newsfile) +15.61%
May-15-25 05:40PM	Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +27.02%
08:30AM	Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview (Business Wire)
08:30AM	Loading…
May-01-25 08:30AM	Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview (Business Wire) +8.33%
Apr-30-25 07:30AM	Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
Apr-28-25 08:30AM	Alpha Cognition to Present ZUNVEYL (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference (Business Wire)
Apr-10-25 08:30AM	Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens (Business Wire)
Apr-01-25 04:27PM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024 (Newsfile)
Mar-31-25 09:50PM	Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript (Seeking Alpha) -8.50%
08:30AM	Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview (Business Wire)
Mar-19-25 04:30PM	Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview (Business Wire)
Mar-18-25 08:30AM	Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease (Business Wire)
Mar-05-25 08:35AM	Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory (Insider Monkey)
Feb-12-25 08:30AM	Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimers disease (Business Wire)
Jan-30-25 11:05AM	Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG) (Newsfile) -5.06%
Jan-22-25 07:00AM	OTC Markets Group Announces Quarterly Index Performance and Rebalancing (GlobeNewswire)
Jan-14-25 08:30AM	Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL (Business Wire)
Jan-08-25 08:30AM	Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimers Disease, in China (Business Wire)
08:30AM	Loading…
Jan-06-25 08:30AM	Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimers Long-Term Care Market During Investor Update Call (Business Wire)
Dec-16-24 02:56PM	Alpha Cognition Announces Partial Exercise of Over-allotment Option (Business Wire) -11.62%
Dec-12-24 06:41PM	Alpha Cognition Announces Voluntary Delisting from CSE (Business Wire) -5.57%
Dec-11-24 08:30AM	Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury (Business Wire)
Nov-15-24 05:00PM	Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update (Business Wire) -5.38% +6.15%
Nov-12-24 09:22AM	Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing (Business Wire) -32.14%

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. It has additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal ("ALPHA-1062IN") formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI, otherwise known as concussion) and ALPHA-0602, ALPHA-0702 & ALPHA-0802. The company was founded in 2000 and is headquartered in Grapevine, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wills Robert James	Director	Aug 18 '25	Buy	8.49	15,000	127,328	15,000	Aug 21 12:36 PM
MERTZ PHILLIP JOSEPH	Director	Aug 18 '25	Sale	9.00	27,778	250,002	22,462	Aug 20 04:26 PM
MERTZ LEONARD POWELL	Director	Aug 18 '25	Buy	9.00	27,778	250,002	121,503	Aug 20 04:06 PM
McFadden Michael E.	Chief Executive Officer	Nov 13 '24	Buy	5.75	2,608	14,996	14,142	Nov 15 04:23 PM
MERTZ LEONARD POWELL	Director	Nov 13 '24	Buy	5.75	8,695	49,996	93,725	Nov 15 04:19 PM
HAVENS JOHN PRENTISS	Director	Nov 13 '24	Buy	5.75	4,347	24,995	273,272	Nov 15 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACOG

Alpha Cognition Inc

Upgrade your FINVIZ experience